Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generics Avoid Many, Not All, Disclosure Requirements For ClinicalTrials.gov

Executive Summary

Generic firms appear to have avoided most, but not all, of the reporting requirements for ClinicalTrials.gov, though winning complete privacy protections appears as though it will require congressional intervention

You may also be interested in...



Generic Approval Standards For Vancomycin Tightened In FDA Draft Guidance

FDA has tightened approval standards for generic oral vancomycin, but appears to have left enough latitude in bioequivalence testing requirements to not greatly impede generic competition

Generic Approval Standards For Vancomycin Tightened In FDA Draft Guidance

FDA has tightened approval standards for generic oral vancomycin, but appears to have left enough latitude in bioequivalence testing requirements to not greatly impede generic competition

FDA Finalizes ODT Guidance, Sticks To More Restrictive Recommendations

FDA drew a line in the sand in finalizing a guidance limiting orally disintegrating tablets to a 30-second dissolution time and 500 mg weight, despite industry arguments that such restrictions would discourage development of ODTs

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS050505

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel